Open AccessIsavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients
Author(s) -
Lauren Fontana,
David S. Perlin,
Yanan Zhao,
Brie N. Noble,
James S. Lewis,
Lynne Strasfeld,
Morgan Hakki
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz282
Subject(s) - medicine , posaconazole , voriconazole , neutropenia , mucormycosis , incidence (geometry) , aspergillosis , hematopoietic stem cell transplantation , surgery , transplantation , immunology , antifungal , dermatology , chemotherapy , physics , optics
Isavuconazole (ISA) is an attractive candidate for primary mold-active prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients. However, data supporting the use of ISA for primary prophylaxis in these patients are lacking.